Skip to main content

Advertisement

Log in

GENE THERAPY

Surrogate gene therapy for muscular dystrophy

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

An engineered truncated gene derived from the dystrophin-related protein (utrophin), prevents pathology without an immune response in an animal model of Duchenne muscular dystrophy (DMD) gene therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1: Utrophin gene therapy for DMD.

References

  1. Guiraud, S. et al. The pathogenesis and therapy of muscular dystrophies. Annu. Rev. Genomics Hum. Genet. 16, 281–308 (2015).

    Article  CAS  Google Scholar 

  2. Song, Y. et al. Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models. Nat. Med. https://doi.org/10.1038/s41591-019-0594-0 (2019).

  3. Duan, D. Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy. Mol. Ther. 26, 2337–2356 (2018).

    Article  CAS  Google Scholar 

  4. Chamberlain, J. R. & Chamberlain, J. S. Progress toward gene therapy for Duchenne muscular dystrophy. Mol. Ther. 25, 1125–1131 (2017).

    Article  CAS  Google Scholar 

  5. Mendell, J. R. et al. Brief report: dystrophin immunity in Duchenne’s muscular dystrophy. N. Engl. J. Med. 363, 1429–1437 (2010).

    Article  CAS  Google Scholar 

  6. Guiraud, S. & Davies, K. E. Pharmacological advances for treatment in Duchenne muscular dystrophy. Curr. Opin. Pharmacol. 34, 36–48 (2017).

    Article  CAS  Google Scholar 

  7. Harper, S. Q. et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med. 8, 253–261 (2002).

    Article  CAS  Google Scholar 

  8. Odom, G. L. et al. Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice. Mol. Ther. 16, 1539–1545 (2008).

    Article  CAS  Google Scholar 

  9. Kennedy, T. L. et al. Micro-utrophin improves cardiac and skeletal muscle function of severely affected D2/mdx mice. Mol. Ther. Methods Clin. Dev. 11, 92–105 (2018).

    Article  CAS  Google Scholar 

  10. Ramos, J. N. et al. Development of novel micro-dystrophins with enhanced functionality. Mol. Ther. 27, 623–635 (2019).

    Article  CAS  Google Scholar 

  11. Crudele, J. M. & Chamberlain, J. S. AAV-based gene therapies for the muscular dystrophies. Hum. Mol. Genet. https://doi.org/10.1093/hmg/ddz128 (2019).

  12. Guiraud, S. et al. The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy. Hum. Mol. Genet. 28, 2189–2200 (2019).

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kay E. Davies.

Ethics declarations

Competing interests

J.S.C. is a member of the Scientific Advisory Board for Solid Biosciences. K.E.D. has no declared conflicts.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Davies, K.E., Chamberlain, J.S. Surrogate gene therapy for muscular dystrophy. Nat Med 25, 1473–1474 (2019). https://doi.org/10.1038/s41591-019-0604-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-019-0604-2

  • Springer Nature America, Inc.

This article is cited by

Navigation